vTv Therapeutics (VTVT) Operating Income (2014 - 2026)
vTv Therapeutics (VTVT) reported Operating Income of $23.3 million for Q1 2026, up 457.73% on a YoY basis from $4.2 million in Q1 2025, and up 395.03% sequentially from -$7.9 million in Q4 2025.
vTv Therapeutics (VTVT) Operating Income (2014 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 13 years of Operating Income data on file, last reported at $23.3 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 457.73% year-over-year to $23.3 million; the trailing twelve-month figure through Mar 2026 stood at -$3.0 million (up 87.86% YoY), and the FY2025 full-year result was -$32.8 million, down 35.68% from the prior year.
- Operating Income grew to $23.3 million in Q1 2026, from -$7.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $23.3 million in Q1 2026 to a low of -$10.7 million in Q3 2025.
- A 5-year average of -$4.8 million and a median of -$6.5 million in 2022 frame the typical range for Operating Income.
- Across the five-year window, Operating Income slumped 254.9% in 2022 and surged 457.73% in 2026, its largest moves.
- Tracing VTVT's Operating Income over 5 years: stood at -$6.3 million in 2022, then rose by 25.79% to -$4.7 million in 2023, then slipped by 3.93% to -$4.9 million in 2024, then tumbled by 61.18% to -$7.9 million in 2025, then soared by 395.03% to $23.3 million in 2026.
- Business Quant data shows VTVT's Operating Income at $23.3 million in Q1 2026, -$7.9 million in Q4 2025, and -$10.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 268.64 Mn |
| 10 | vTv Therapeutics | 19.07 Mn | 19.07 Mn | - | 23.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.26 Mn |
| Dec 31, 2025 | -7.89 Mn |
| Sep 30, 2025 | -10.70 Mn |
| Jun 30, 2025 | -7.72 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -4.89 Mn |
| Sep 30, 2024 | -6.51 Mn |
| Jun 30, 2024 | -7.16 Mn |
| Mar 31, 2024 | -5.63 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -5.37 Mn |
| Jun 30, 2023 | -8.00 Mn |
| Mar 31, 2023 | -7.43 Mn |
| Dec 31, 2022 | -6.34 Mn |
| Sep 30, 2022 | -5.69 Mn |
| Jun 30, 2022 | -4.03 Mn |
| Mar 31, 2022 | -6.48 Mn |
| Dec 31, 2021 | -11.11 Mn |
| Sep 30, 2021 | -1.60 Mn |
| Jun 30, 2021 | -4.67 Mn |